DISSOLUTION BEHAVIOR, STABILITY AND ANTI-INFLAMMATORY ACTIVITY OF KETOPROFEN COATED TRIPOLYPHOSPHATE MODIFIED CHITOSAN NANOPARTICLE

Jaya Hardi; Purwantiningsih Sugita; Laksmi Ambarsari

doi:10.22146/ijc.21298

DISSOLUTION BEHAVIOR, STABILITY AND ANTI-INFLAMMATORY ACTIVITY OF KETOPROFEN COATED TRIPOLYPHOSPHATE MODIFIED CHITOSAN NANOPARTICLE

https://doi.org/10.22146/ijc.21298

Jaya Hardi⁽¹⁾, Purwantiningsih Sugita^(2*), Laksmi Ambarsari⁽³⁾

(1) Chemistry Department, Science and Mathematic Faculty of Tadulako University, Bumi Tadulako Tondo Campus, Palu Sulawesi Tengah 94111
(2) Chemistry Department, Science and Mathematic Faculty, Bogor Agricultural University, Fapet Building W2 Lt 4-5, Jl Agatis Kampus IPB Darmaga Bogor 16680
(3) 3Biochemistry Department, Science and Mathematic Faculty, Bogor Agricultural University, Fapet Building W5 Lt 5 Jl Agatis Kampus IPB Darmaga Bogor 16680
(*) Corresponding Author

Abstract

Ketoprofen coated tripolyphosphate modified chitosan nanoparticle was resulted from ionic gelation process by ultrasonication, centrifugation, and spray dry methods. Particle was analyzed by particle Size Analyzer. Dissolution and stability of them have conducted by Row Hansen methods at 37±0.5 °C and 150 rpm and using climatic chamber at 40±2 °C and relative humidity 75±5% for 3 months, respectively. Anti-inflammatory activities have conducted by Plate Reader methods. The result showed that B formulae have particles diameter of 563.1±157.5 nm and entrapment efficiency of 89.663%, respectively. Dissolution behavior showed that ketoprofen restrained released within acid medium and maximum released within base medium of 11.35-15.87% and 45.73-99.25%, respectively. Kinetically, dissolution of ketoprofen within intestinal and gastric pH condition was Korsmeyers-Peppas kinetic models. While, stability behavior showed that B formula has ketoprofen percentage left in nanocapsule after 3 months greater than 90% with water content and shelf life of 19.68%, and 14.19 week, respectively, and degradation kinetic model followed Avrami-Eroveef equation. Anti-inflammation test showed that B formula had the COX-2 inhibitory activity of 90.86% is higher than free ketoprofen.

Keywords

nanoparticles; ketoprofen; dissolution; stabilities; anti-inflammatory

Full Text:

Full Text PDF

References

[1] Schroeder, A., Kost, J., and Barenholz, Y., 2009, Chem. Phys. Lipids, 162, 1-2, 1–16.

[2] Hielscher, T., 2005, Ultrasonic production of nano-size dispersions and emulsions, in: Proceedings of European Nanosystems Conference ENS’05 Paris, France, 14-16 December 2005.

[3] Nakorn, P.N., 2008, J. Met. Mater. Miner., 18 2, 73–77.

[4] Saha, P., Goyal, A.K., and Rath, G., 2010, Trop. J. Pharm. Res., 9, 5, 483–488.

[5] Sugita, P., Ambarsari, L., and Farichah, F., 2013, Int. J. Res. Rev. Appl. Sci., 14, 3, 612–618.

[6] Sugita P., Ambarsari L., Sari Y.A., and Nugraha Y. 2013. Int. J. Res. Rev. Appl. Sci., 14, 1, 141–149.

[7] Sugita, P., Napthaleni, Kurniati, M., and Wukirsari T., 2010, Makara Sci. Ser., 14, 1, 107–112.

[8] Latifah, S., Sugita, P., and Srijanto, B., 2010, Stabilitas mikrokapsul ketoprofen tersalut kitosan-alginat, in Prosiding Seminar Nasional Sains III; Fakultas MIPA Institut Pertanian Bogor, 13 November 2010, 248–259.

[9] Lu, W-L., Zhang, Q., Zheng, L., Wang, H., Li, R-Y., Zhang, L-F., Shen, W-B., and Tu, X-D., 2004, Biol. Pharm. Bull., 27, 10, 1515–1520.

[10] Departemen Kesehatan RI, 1995, Farmakope Indonesia, Ed. Ke-4, Jakarta.

[11] Shoaib, M.H., Tazeen, J., Merchant, H.A., and Yousuf, R.I., 2006, J. Pharm. Sci., 19, 2, 119–124.

[12] Sarvanan, M., Nataraj, K.S., and Ganesh, K.S., 2007, Chem. Pharm. Bull., 51, 8, 978–983.

[13] Sugita, P., Srijanto, B., Arifin, B., and Setyowati, E.V., 2009, Indo. J. Chem., 9, 3, 391–397.

[14] Berger, J., Reist, M., Mayera, J.M., Felt, O., and Gurny, R., 2004, Eur. J. Pharm. Biopharm., 57, 1, 35–52.

[15] Levenspiel, O., 1999, Chemical Reaction Engineering, 3^rd ed., John Wiley & Sons, New York.

[16] Cayman Chemical Company, 2002, Colorimetric COX ovine inhibitor screening assay, kit no. 760111. USA.

[17] Patel, J.K., and Jivani N.P., 2009, Int. J. Pharm. Sci. Nanotechnol., 2, 2, 517–522.

[18] Kaur, S.P., Rao, R., Hussain, A., and Khatkar, S., 2011, J. Pharm. Sci. Res., 3, 5, 1227–1232.

[19] Sugita, P., Achmadi, S.S., and Yundhana, Y., 2010, J. Nat. Indonesia, 13, 1, 21–26.

[20] Li, P., Dai, Y-N, Zhang, J-P, Wang, A-Q., and Wei, Q., 2008, Int. J. Biomed. Sci., 4, 3, 221–228.

[21] Najmuddin, M., Ahmed, A., Shelar, S., Patel, V., and Khan, T., 2010, Int. J. Pharm. Pharm. Sci., 2, 2, 164-168.

[22] Sutriyo, Joshita, D., and Rosari, I., 2005, Majalah Ilmu Kefarmasian, 2, 3,145–153.

[23] Sugita, P., Asnel, R.S., Arifin, B., and Wukirsari, T., 2010, Indo. J. Chem., 10, 3, 269–275.

[24] Kim, M-S., Kim, J-S., and Hwang, S-J., 2007, Chem. Pharm. Bull., 55, 11, 1631–1634.

[25] Menteri Kesehatan, 1994, Keputusan Menteri Kesehatan Republik Indonesia Nomor: 661/MENKES/SK/VII/1994 Tentang persyaratan obat tradisional, Jakarta.

[26] Janardhan, D., Llingam, M., Mohan, C.K., and Venkateswarlu, V., 2008, Int. J. Pharm. Sci. Nanotechnol., 1, 3, 227–232.

[27] van Drooge D.J., Hinrichs, W.L., Dickhoff, B.H., Elli, M.N., Visser, M.R., Zijlstra, G.S., and Frijlink, H.W., 2005, Eur. J. Pharm. Sci., 26, 2, 231–240.

DOI: https://doi.org/10.22146/ijc.21298